
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
David Gerber, MD discusses treating Lambert-Eaton Myasthenic Syndrome in patients with small-cell lung cancer based on updated guidelines.
David Gerber, MD discusses treating Lambert-Eaton Myasthenic Syndrome in patients with small-cell lung cancer based on updated guidelines.






